Krishna Institute of Medical Sciences quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	1,180	872	+35.3%
EBITDA	223	193	+16.0%
EBITDA margin	18.9%	22.1%	−3.2 pts
Profit before tax	55.6	114	−51.1%
Net profit	37.4	85.0	−56.0%
EPS	₹1.04	₹1.96	−46.9%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	1,180	1,075	998	961	872	797	772	777	688	634	606	652	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	16.4	9.7	5.2	4.2	7.1	4.5	17.8	5.0	4.6	3.8	3.3	2.9
	1,196	1,084	1,003	965	879	801	790	782	693	638	609	655
	261	235	211	204	192	169	170	157	145	135	124	143
	−16.2	−2.6	−14.3	−8.3	−7.7	−2.1	−8.0	−1.1	−2.2	−0.9	1.1	−2.1
	213	180	176	175	151	134	128	119	119	109	104	106
	83.4	68.1	56.8	45.0	32.6	26.7	25.7	19.9	17.9	16.4	12.4	8.9
	101	85.0	78.7	66.1	53.4	52.6	44.7	41.0	39.0	46.3	35.4	32.6
	499	455	426	387	344	298	296	285	248	232	229	229
	1,140	1,021	934	868	765	678	656	620	566	537	507	517
	223	207	199	204	193	198	187	218	179	159	147	177
	123	122	120	138	139	145	143	177	140	113	112	145
Profit
	55.6	63.1	68.6	97.1	114	123	135	162	127	100	103	139
	0.0	−10.9	0.0	−0.3	0.0	10.8	0.0	0.0	0.0	0.0	0.0	−0.0
	55.6	52.2	68.6	96.8	114	134	135	162	127	100	103	139
	33.8	34.8	33.1	37.7	32.4	35.7	35.3	45.0	33.8	28.7	21.9	37.2
	−14.6	−13.1	−16.4	−12.9	−3.7	−7.8	6.8	−3.5	−1.9	−0.2	4.0	0.2
	19.2	21.7	16.7	24.8	28.7	27.9	42.1	41.5	31.9	28.5	25.9	37.3
	1.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.1	−0.1	0.0
	37.4	33.1	51.9	72.0	85.0	106	92.5	121	95.2	71.5	76.6	101
	36.4	30.5	51.9	72.0	85.0	106	92.5	121	95.2	71.6	76.7	101
	0.0	0.4	0.0	0.3	−0.5	0.8	−0.9	−2.3	0.1	−0.3	0.2	0.2
	37.4	33.5	51.9	72.3	84.5	107	91.6	118	95.3	71.2	76.8	101
	41.5	42.5	53.4	67.1	78.6	102	—	107	86.6	65.5	71.8	92.2
	−4.1	−9.4	−1.5	5.2	6.4	4.3	—	13.3	8.6	6.0	4.7	9.3
Per share
	₹1.04	₹1.06	₹1.33	₹1.67	₹1.96	₹2.54	₹2.22	₹2.68	₹10.82	₹8.18	₹8.98	₹11.50
	₹1.04	₹1.06	₹1.33	₹1.67	₹1.96	₹2.54	₹2.22	₹2.68	₹10.82	₹8.18	₹8.98	₹11.50
Other comprehensive income — detail
	0.0	0.4	0.0	0.3	−0.5	0.8	—	—	—	—	—	—
	0.0	−0.4	0.0	−0.4	0.6	−1.1	—	—	—	—	—	—
	—	—	—	—	—	—	1.2	3.1	−0.1	0.4	−0.2	−0.3
	0.0	0.0	0.0	0.1	−0.1	0.3	—	—	—	—	—	—
	—	—	—	—	—	—	−0.3	−0.8	0.0	−0.1	0.0	0.1
	41.5	42.8	53.4	67.3	78.2	103	88.0	105	86.7	65.2	72.1	92.4
	−4.1	−9.3	−1.5	5.3	6.3	4.4	3.6	13.0	8.6	6.0	4.7	9.3
Per share — as-filed variants
	₹1.04	₹1.06	₹1.33	₹1.67	₹1.96	₹2.54	₹2.22	₹2.68	₹10.82	₹8.18	₹8.98	₹11.50
	₹1.04	₹1.06	₹1.33	₹1.67	₹1.96	₹2.54	₹2.22	₹2.68	₹10.82	₹8.18	₹8.98	₹11.50
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	935	842	801	766	688	630	611	622	546	499	480	512
	79.3%	78.3%	80.3%	79.7%	78.9%	79.0%	79.1%	80.0%	79.3%	78.8%	79.3%	78.5%
Adjusted (ex-exceptional items) — derived
	55.6	63.1	68.6	97.1	114	123	135	162	127	100	103	139
	0.0	−10.9	0.0	−0.3	0.0	10.8	0.0	0.0	0.0	0.0	0.0	−0.0
	37.4	39.5	51.9	72.2	85.0	97.5	92.5	121	95.2	71.5	76.6	101
	₹1.04	₹1.26	₹1.33	₹1.68	₹1.96	₹2.34	₹2.22	₹2.68	₹10.82	₹8.18	₹8.98	₹11.50

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

KIMS₹704.60

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAPOLLOHOSP MAXHEALTH FORTIS JUBLPHARMA INDGN ONESOURCE PFIZER POLYMEDMcap ₹28,184 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	652.5	605.8	633.8	688.4	777.3	772.4	796.9	871.6	960.7	997.7	1,074.6	1,179.5
Other Income	2.9	3.3	3.8	4.6	5.0	17.8	4.5	7.1	4.2	5.2	9.7	16.4
Total Income	655.4	609.1	637.6	693.0	782.3	790.2	801.4	878.7	964.9	1,002.9	1,084.3	1,195.9
Expenses
+ Purchases of Stock-in-Trade	142.5	124.5	135.2	144.8	156.6	169.8	169.2	191.7	203.5	211.2	235.4	260.9
+ Changes in Inventories	-2.1	1.1	-0.9	-2.2	-1.1	-8.0	-2.1	-7.7	-8.3	-14.3	-2.6	-16.2
+ Employee Benefit Expense	105.7	104.3	108.5	118.6	119.2	127.5	134.1	151.0	174.5	176.3	179.9	212.6
+ Finance Costs	8.9	12.4	16.4	17.9	19.9	25.7	26.7	32.6	45.0	56.8	68.1	83.4
+ Depreciation & Amortisation	32.6	35.4	46.3	39.0	41.0	44.7	52.6	53.4	66.1	78.7	85.0	100.8
+ Other Expenses	229.1	228.9	232.0	247.8	284.5	295.9	297.7	344.0	387.0	425.6	455.4	498.8
Total Expenses	516.7	506.5	537.5	565.9	620.1	655.6	678.2	765.0	867.8	934.3	1,021.2	1,140.3
EBITDA	177.3	147.1	159.0	179.4	218.1	187.2	198.0	192.6	204.0	198.9	206.5	223.4
EBIT	144.7	111.7	112.7	140.4	177.1	142.5	145.4	139.2	137.9	120.2	121.5	122.6
Profit
PBT before Exceptional Items	138.6	102.6	100.1	127.1	162.2	134.6	123.2	113.7	97.1	68.6	63.1	55.6
+ Exceptional Items	-0.0	0.0	0.0	0.0	0.0	0.0	10.8	0.0	-0.3	0.0	-10.9	0.0
Pretax Income	138.6	102.6	100.1	127.1	162.2	134.6	134.0	113.7	96.8	68.6	52.2	55.6
+ Current Tax	37.2	21.9	28.7	33.8	45.0	35.3	35.7	32.4	37.7	33.1	34.8	33.8
+ Deferred Tax	0.2	4.0	-0.2	-1.9	-3.5	6.8	-7.8	-3.7	-12.9	-16.4	-13.1	-14.6
Tax Expense	37.3	25.9	28.5	31.9	41.5	42.1	27.9	28.7	24.8	16.7	21.7	19.2
+ Share of Associates & JVs	0.0	-0.1	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	1.0
Net Income	101.3	76.6	71.5	95.2	120.7	92.5	106.1	85.0	72.0	51.9	33.1	37.4
+ Net Income — Continuing Ops	101.3	76.7	71.6	95.2	120.7	92.5	106.1	85.0	72.0	51.9	30.5	36.4
+ Other Comprehensive Income	0.2	0.2	-0.3	0.1	-2.3	-0.9	0.8	-0.5	0.3	0.0	0.4	0.0
Total Comprehensive Income	101.5	76.8	71.2	95.3	118.4	91.6	106.9	84.5	72.3	51.9	33.5	37.4
Net Income to Common	92.2	71.8	65.5	86.6	107.4	—	101.8	78.6	67.1	53.4	42.5	41.5
Minority Interest	9.3	4.7	6.0	8.6	13.3	—	4.3	6.4	5.2	-1.5	-9.4	-4.1
Per Share
Basic EPS	11.50	8.98	8.18	10.82	2.68	2.22	2.54	1.96	1.67	1.33	1.06	1.04
Diluted EPS	11.50	8.98	8.18	10.82	2.68	2.22	2.54	1.96	1.67	1.33	1.06	1.04
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.8	-0.5	0.3	0.0	0.4	0.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-1.1	0.6	-0.4	0.0	-0.4	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.3	-0.2	0.4	-0.1	3.1	1.2	—	—	—	—	—	—
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.3	-0.1	0.1	0.0	0.0	0.0
+ Tax on Items to be Reclassified — alt tag	0.1	0.0	-0.1	0.0	-0.8	-0.3	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	92.4	72.1	65.2	86.7	105.4	88.0	102.5	78.2	67.3	53.4	42.8	41.5
Comprehensive Income — Non-controlling Interests	9.3	4.7	6.0	8.6	13.0	3.6	4.4	6.3	5.3	-1.5	-9.3	-4.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	11.50	8.98	8.18	10.82	2.68	2.22	2.54	1.96	1.67	1.33	1.06	1.04
Diluted EPS — Continuing Operations	11.50	8.98	8.18	10.82	2.68	2.22	2.54	1.96	1.67	1.33	1.06	1.04
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	512.1	480.3	499.5	545.8	621.8	610.6	629.8	687.6	765.5	800.8	841.8	934.8
Gross Margin %	78.48	79.27	78.81	79.29	79.99	79.05	79.03	78.89	79.68	80.26	78.34	79.25
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	138.6	102.6	100.1	127.1	162.2	134.6	123.2	113.7	97.1	68.6	63.1	55.6
− Exceptional Items (reconciliation)	-0.0	0.0	0.0	0.0	0.0	0.0	10.8	0.0	-0.3	0.0	-10.9	0.0
Net Income Adj (tax-effected)	101.3	76.6	71.5	95.2	120.7	92.5	97.5	85.0	72.2	51.9	39.5	37.4
EPS Adj	11.50	8.98	8.18	10.82	2.68	2.22	2.34	1.96	1.68	1.33	1.26	1.04
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	2.00	2.00	2.00	2.00	2.00	—	2.00	2.00
Paid Up Equity Capital	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	80.0	84.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Krishna Institute of Medical Sciences Q2 FY27 results date

Krishna Institute of Medical Sciences (NSE: KIMS) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 26 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹41.5 crore, down 47.2% from ₹78.6 crore in Q1 FY26 and down 2.4% from ₹42.5 crore in Q4 FY26. Revenue from operations was ₹1,180 crore, up 35.3% year on year and up 9.8% from the previous quarter.

Board-meeting notice filed: 26 October 2026
Q2 FY26 results (a year earlier): 7 November 2025
Q1 FY27 results (the latest): 3 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 26 Oct
Q1 FY27 net profit: ₹41.5 Cr−47.2% vs Q1 FY26−2.4% vs Q4 FY26
Q1 FY27 revenue: ₹1,180 Cr+35.3% vs Q1 FY26+9.8% vs Q4 FY26
Q1 FY27 operating margin: 10.4%−5.6 pts vs Q1 FY26−0.9 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹67.1 CrRevenue ₹961 Cr
Q1 FY27 EPS (basic): ₹1.04

Questions

When will Krishna Institute of Medical Sciences announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 26 October 2026). Last year it reported Q2 FY26 on 7 November 2025.

What will Krishna Institute of Medical Sciences' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹67.1 crore and revenue from operations ₹961 crore. The latest quarter, Q1 FY27, had a net profit of ₹41.5 crore and revenue of ₹1,180 crore.

What was Krishna Institute of Medical Sciences' revenue in FY26?

Revenue from operations was ₹3,905 crore in FY26 (April 2025–March 2026), up 28.6% from ₹3,035 crore in FY25. It was ₹2,498 crore in FY24 and ₹2,198 crore in FY23: up 77.7% over three years, 21.1% a year on average.

What were Krishna Institute of Medical Sciences' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹41.5 crore, down 47.2% from ₹78.6 crore in Q1 FY26 and down 2.4% from ₹42.5 crore in Q4 FY26. Revenue from operations was ₹1,180 crore, up 35.3% year on year and up 9.8% from the previous quarter.

How has Krishna Institute of Medical Sciences' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹67.1 crore in Q2 FY26, ₹53.4 crore in Q3 FY26, ₹42.5 crore in Q4 FY26 and ₹41.5 crore in Q1 FY27. That is ₹205 crore over the four quarters, down 46.2% from ₹380 crore in the four quarters before. Revenue from operations: ₹961 crore, ₹998 crore, ₹1,075 crore and ₹1,180 crore.

What was Krishna Institute of Medical Sciences' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹241 crore in FY26 (April 2025–March 2026), down 37.2% from ₹385 crore in FY25. It was ₹310 crore in FY24 and ₹336 crore in FY23: down 28.2% over three years, an average fall of 10.5% a year.

Where do these Krishna Institute of Medical Sciences figures come from?

From Krishna Institute of Medical Sciences' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.